Heart attack patients may ditch aspirin sooner with new stent

NCT ID NCT05785897

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a new drug-coated stent and a blood thinner strategy without aspirin for people who have had a severe heart attack. The goal is to see if this approach lowers the risk of serious bleeding while still preventing future heart attacks, strokes, or the need for another procedure. About 350 participants will be randomly assigned to either the new stent plus a single blood thinner, or the standard stent plus two blood thinners (including aspirin) for 6-12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

sirolimus-based nanocarrier eluting stent and P2Y12 inhibitor (ticagrelor or prasugrel) without aspirin

What this could lead to

If successful, this could offer a safer treatment option after a heart attack, reducing bleeding risk while still preventing future heart problems.

What could go wrong

This is a mid-sized trial, and the new approach may not be as effective at preventing stent clotting or heart attacks as the standard dual therapy. Bleeding risks, though potentially lower, still exist.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Geneva University Hospitals

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Zurich University Hospital

    RECRUITING

    Zurich, Switzerland

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••